A comparison between triple and quadruple therapy efficacy in eradication of Helicobacter pylori in patients with dyspepsia
Phase 1
- Conditions
- Helicobacter Pylori.Helicobacter pylori [H.pylori] as the cause of diseases classified to other chapters
- Registration Number
- IRCT2016012623736N2
- Lead Sponsor
- orestan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 321
Inclusion Criteria
The age of greater than 40 years; A positive family history of gastric cancer or patients who have signs and symptom sof gastric cancer; Also patients among whom, the symptoms have not ameliorated; despite a 6-week PPI therapy; and who have a positive biopsy.
Exclusion criteria:
Age less than 18 years; A positive history of allergic reaction to each of the medications used in this study; A history of eradication of Helicobacter pylori; A recent history (last month)of antibiotic therapy in each patient or pregnancy
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The eradication of Helicobacter pylori in group A. Timepoint: 6week. Method of measurement: Carbon 13 urea breathing test.;Failure to eradicate Helicobacter pylori in group A. Timepoint: 6 week. Method of measurement: Carbon 13 urea breathing test.;The eradication of Helicobacter pylori in group A. Timepoint: 6 week. Method of measurement: Carbon 13 urea breathing test.;The eradication of Helicobacter pylori in group C. Timepoint: 6 week. Method of measurement: Carbon 13 urea breathing test.;Failure to eradicate Helicobacter pylori in group B. Timepoint: 6 week. Method of measurement: Carbon 13 urea breathing test.;Failure to eradicate Helicobacter pylori in group C. Timepoint: 6 week. Method of measurement: Carbon 13 urea breathing test.
- Secondary Outcome Measures
Name Time Method The development of side effects of medications used in this study in any of the patients in Group A. Timepoint: 6 week. Method of measurement: Patients’comments and examination by physician.;The development of side effects of medications used in this study in any of the patients in Group B. Timepoint: 6 week. Method of measurement: Patients’comments and examination by physician.;The development of side effects of medications used in this study in any of the patients in Group C. Timepoint: 6 week. Method of measurement: Patients’comments and examination by physician.